Ivo Kocák

4.7k total citations · 2 hit papers
41 papers, 3.3k citations indexed

About

Ivo Kocák is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ivo Kocák has authored 41 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Ivo Kocák's work include Cancer Treatment and Pharmacology (11 papers), Prostate Cancer Treatment and Research (11 papers) and Colorectal Cancer Treatments and Studies (7 papers). Ivo Kocák is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Prostate Cancer Treatment and Research (11 papers) and Colorectal Cancer Treatments and Studies (7 papers). Ivo Kocák collaborates with scholars based in Czechia, France and United Kingdom. Ivo Kocák's co-authors include Johann S. de Bono, Gwénaëlle Gravis, Liji Shen, Oliver Sartor, Mustafa Özgüroğlu, Steinbjørn Hansen, Stéphane Oudard, I. Bodrogi, Mary J. MacKenzie and Sunil Gupta and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Ivo Kocák

38 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

2010 2.4k citations Johann S. de Bono, Stéphane Oudard et al. The Lancet profile →
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

2018 281 citations Noel W. Clarke, Paweł Wiechno et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ivo Kocák Czechia	13	2.5k	1.4k	937	798	724	41	3.3k
Liji Shen United States	16	2.8k 1.1×	1.3k 0.9×	1.1k 1.2×	946 1.2×	620 0.9×	37	3.5k
Martin Roessner United States	8	2.2k 0.9×	961 0.7×	897 1.0×	695 0.9×	511 0.7×	11	2.9k
Susan Feyerabend United Kingdom	21	3.2k 1.3×	1.0k 0.7×	1.0k 1.1×	1.1k 1.4×	726 1.0×	71	3.9k
David Lorente Spain	28	1.8k 0.7×	1.2k 0.9×	653 0.7×	1.1k 1.3×	594 0.8×	100	2.9k
J Horti Hungary	9	3.6k 1.5×	1.6k 1.2×	1.2k 1.3×	1.1k 1.4×	1.0k 1.4×	17	4.6k
Jean-Pascal Machiels Belgium	18	2.4k 1.0×	2.0k 1.5×	1.0k 1.1×	848 1.1×	960 1.3×	36	4.5k
William R. Berry United States	11	3.9k 1.6×	1.8k 1.3×	1.3k 1.4×	1.1k 1.4×	985 1.4×	22	4.9k
Daniel Petrylak United States	6	1.9k 0.8×	813 0.6×	726 0.8×	592 0.7×	453 0.6×	8	2.4k
Stephen D. Rubin United States	13	1.3k 0.5×	2.6k 1.9×	811 0.9×	673 0.8×	1.1k 1.5×	17	4.0k
John C. Araujo United States	25	1.4k 0.6×	1.1k 0.8×	509 0.5×	567 0.7×	851 1.2×	89	2.5k

Countries citing papers authored by Ivo Kocák

Since Specialization

Citations

This map shows the geographic impact of Ivo Kocák's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivo Kocák with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivo Kocák more than expected).

Fields of papers citing papers by Ivo Kocák

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivo Kocák. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivo Kocák. The network helps show where Ivo Kocák may publish in the future.

Co-authorship network of co-authors of Ivo Kocák

This figure shows the co-authorship network connecting the top 25 collaborators of Ivo Kocák. A scholar is included among the top collaborators of Ivo Kocák based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivo Kocák. Ivo Kocák is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Xinlei, Ivo Kocák, Qian Yang, et al.. (2025). TAT-CRE inhalation enables tumor induction corresponding to adenoviral Cre-recombinase in a lung cancer mouse model. Communications Biology. 8(1). 741–741.

Selingerová, Iveta, et al.. (2022). Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients. Current Oncology. 29(6). 4138–4147. 2 indexed citations

Saad, Fred, Antoine Thiery-Vuillemin, Paweł Wiechno, et al.. (2022). Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology. 23(10). 1297–1307. 21 indexed citations

Navrátil, Jiří, et al.. (2019). Oligometastatic Prostate Cancer. Klinicka onkologie. 32(2). 97–100. 1 indexed citations

Clarke, Noel W., Paweł Wiechno, B. Yа. Alekseev, et al.. (2018). Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology. 19(7). 975–986. 281 indexed citations breakdown →

Clarke, Noel W., Paweł Wiechno, B. Yа. Alekseev, et al.. (2018). Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.. Journal of Clinical Oncology. 36(15_suppl). 5003–5003. 4 indexed citations

Bono, Johann S. de, Ugo De Giorgi, Christophe Massard, et al.. (2016). PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 27. vi243–vi243. 40 indexed citations

Kostřica, Rom, et al.. (2016). Genetic risk factors of cisplatin induced ototoxicity in adult patients. Neoplasma. 63(2). 263–8. 21 indexed citations

Kocáková, Ilona, Ivo Kocák, Andrea Jurečková, et al.. (2015). Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours. Bratislavské lekárske listy/Bratislava medical journal. 116(4). 218–221. 2 indexed citations

10.

Bahl, Amit, Stéphane Oudard, Bertrand Tombal, et al.. (2013). Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Annals of Oncology. 24(9). 2402–2408. 118 indexed citations

11.

Sartor, Oliver, Stéphane Oudard, Mustafa Özgüroğlu, et al.. (2012). Prognostic factors for survival in the phase III TROPIC trial.. Journal of Clinical Oncology. 30(5_suppl). 102–102. 3 indexed citations

12.

Rossi, JF, Sylvie Négrier, Nicholas D. James, et al.. (2010). A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. British Journal of Cancer. 103(8). 1154–1162. 152 indexed citations

13.

Bono, Johann S. de, Stéphane Oudard, Mustafa Özgüroğlu, et al.. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. 376(9747). 1147–1154. 2397 indexed citations breakdown →

14.

Poprach, Alexandr, Katarína Petráková, J Vyskočil, et al.. (2008). KARDIOTOXICITA LÉKŮ POUŽÍVANÝCH V ONKOLOGII. Klinicka onkologie. 21.

15.

Poprach, Alexandr, Katarína Petráková, J Vyskocil, et al.. (2008). [Cardiotoxicity of drugs used in oncology].. PubMed. 21(5). 288–93. 3 indexed citations

16.

Michálek, Jaroslav, Ivo Kocák, Vuk Fait, Jan Žaloudík, & Roman Hájek. (2007). Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma. The Journal of Immunology. 178(11). 6789–6795. 10 indexed citations

17.

Dušek, Ladislav, et al.. (2005). Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients.. PubMed. 52(4). 330–7. 12 indexed citations

18.

Kocák, Ivo, et al.. (2003). Interferon Inducibility of STAT 1 Activation and Its Prognostic Significance in Melanoma Patients. Folia Biologica. 49(4). 142–146. 10 indexed citations

19.

Lauerová, L, et al.. (2002). Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.. PubMed. 49(3). 159–66. 80 indexed citations

20.

Kocák, Ivo, et al.. (1999). [Treatment with interferon and autoimmunity].. PubMed. 45(7). 409–13. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact